The Conservative and Interventional Treatment of the Complications of Liver Cirrhosis

被引:8
作者
Sauerbruch, Tilman [1 ]
Appenrodt, Beate [2 ]
Schmitz, Volker [3 ]
Spengler, Ulrich [1 ]
机构
[1] Univ Hosp Bonn, Dept Internal Med 1, Bonn, Germany
[2] Univ Saarland, Dept Internal Med 2, D-66123 Saarbrucken, Germany
[3] St Marienworth Hosp, Bad Kreuznach, Germany
来源
DEUTSCHES ARZTEBLATT INTERNATIONAL | 2013年 / 110卷 / 08期
关键词
INTRAHEPATIC PORTOSYSTEMIC SHUNT; HEPATIC-ENCEPHALOPATHY; HEPATORENAL-SYNDROME; SECONDARY PROPHYLAXIS; DIAGNOSIS; METAANALYSIS; PARACENTESIS; MANAGEMENT; LIGATION; THERAPY;
D O I
10.3238/arztebl.2013.0126
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: It is estimated that 1 million persons in Germany suffer from hepatic cirrhosis, which is the final stage of chronic inflammation of the liver. Cirrhosis has multiple causes, all of which lead to structural changes of the liver and to portal hypertension. The main complications of cirrhosis arise in turn: These include bleeding from collateral veins, ascites, hepatocellular carcinoma, encephalopathy, and infection leading to organ failure. Methods: We present the treatment of the main complications of liver cirrhosis with reference to the relevant literature (phase II and III trials, meta-analyses, and reviews). Results: Endoscopic treatment (ligation) is used for the primary and secondary prophylaxis of variceal bleeding. Drugs to lower portal pressure (e.g., beta-blockers) are an established means of preventing initial or recurrent variceal bleeding over the long term. Vasoconstrictors such as terlipressin are mainly used to treat acute hemorrhage and type 1 hepatorenal syndrome. The main treatment of ascites is with spironolactone, in combination with a loop diuretic where indicated. A shunt (TIPS) is used to treat severe or repeat variceal hemorrhage or refractory ascites. Antibiotics play a well-established role in the treatment of acute hemorrhage, in the treatment and prevention of spontaneous bacterial peritonitis, and in the treatment of encephalopathy. The treatment of hepatocellular carcinoma depends on its extent of spread and on the degree of decompensation of cirrhosis. Conclusion: For most of the main complications of liver cirrhosis, there are treatments that have been well-tested in randomized trials. Liver transplantation should also be considered in every case.
引用
收藏
页码:126 / U21
页数:8
相关论文
共 49 条
[1]   Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials [J].
Als-Nielsen, B ;
Gluud, LL ;
Gluud, C .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7447) :1046-1050
[2]   Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents [J].
Angermayr, B ;
Cejna, M ;
Koenig, F ;
Karnel, F ;
Hackl, F ;
Gangl, A ;
Peck-Radosavljevic, M .
HEPATOLOGY, 2003, 38 (04) :1043-1050
[3]   Infections in Patients With Cirrhosis Increase Mortality Four-Fold and Should Be Used in Determining Prognosis [J].
Arvaniti, Vasiliki ;
D'Amico, Gennaro ;
Fede, Giuseppe ;
Manousou, Pinelopi ;
Tsochatzis, Emmanuel ;
Pleguezuelo, Maria ;
Burroughs, Andrew Kenneth .
GASTROENTEROLOGY, 2010, 139 (04) :1246-+
[4]   Effectiveness of Combined Pharmacologic and Ligation Therapy in High-Risk Patients With Acute Esophageal Variceal Bleeding [J].
Augustin, Salvador ;
Altamirano, Jose ;
Gonzalez, Antonio ;
Dot, Joan ;
Abu-Suboh, Monder ;
Ramon Armengol, Josep ;
Azpiroz, Fernando ;
Esteban, Rafael ;
Guardia, Jaime ;
Genesca, Joan .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (10) :1787-1795
[5]   Review article: the modern management of hepatic encephalopathy [J].
Bajaj, J. S. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (05) :537-547
[6]   Rifaximin Improves Driving Simulator Performance in a Randomized Trial of Patients With Minimal Hepatic Encephalopathy [J].
Bajaj, Jasmohan S. ;
Heuman, Douglas M. ;
Wade, James B. ;
Gibson, Douglas P. ;
Saeian, Kia ;
Wegelin, Jacob A. ;
Hafeezullah, Muhammad ;
Bell, Debulon E. ;
Sterling, Richard K. ;
Stravitz, R. Todd ;
Fuchs, Michael ;
Luketic, Velimir ;
Sanyal, Arun J. .
GASTROENTEROLOGY, 2011, 140 (02) :478-U179
[7]   Rifaximin Treatment in Hepatic Encephalopathy [J].
Bass, Nathan M. ;
Mullen, Kevin D. ;
Sanyal, Arun ;
Poordad, Fred ;
Neff, Guy ;
Leevy, Carroll B. ;
Sigal, Samuel ;
Sheikh, Muhammad Y. ;
Beavers, Kimberly ;
Frederick, Todd ;
Teperman, Lewis ;
Hillebrand, Donald ;
Huang, Shirley ;
Merchant, Kunal ;
Shaw, Audrey ;
Bortey, Enoch ;
Forbes, William P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (12) :1071-1081
[8]   Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study [J].
Brensing, KA ;
Textor, J ;
Perz, J ;
Schiedermaier, P ;
Raab, P ;
Strunk, H ;
Klehr, HU ;
Kramer, HJ ;
Spengler, U ;
Schild, H ;
Sauerbruch, T .
GUT, 2000, 47 (02) :288-295
[9]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[10]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022